Related Experiment Video
Updated: May 28, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Immune Checkpoint-Based Therapies in Colorectal Cancer-Current Approaches and Future Perspectives.
Katarzyna Nakielska1,2, Jacek Plewka1, Marzena Lenart2
1Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland.
International Journal of Molecular Sciences
|May 27, 2026
Summary
Colorectal cancer (CRC) immunotherapies targeting immune checkpoints show promise but have limited efficacy. This review explores current treatments, clinical trials, and novel strategies like small-molecule inhibitors for better CRC treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Cancer Therapeutics
Background:
- Colorectal cancer (CRC) is a leading cause of cancer mortality globally.
- Tumor immune evasion via immune checkpoints impairs antitumor responses.
- Current immune checkpoint inhibitors (ICIs) offer limited efficacy in CRC.
Purpose of the Study:
- To review approved ICI therapies for cancer, focusing on CRC.
- To discuss ongoing clinical trials and emerging trends in CRC immunotherapy.
- To explore novel therapeutic strategies, including small-molecule inhibitors.
Main Methods:
- Comprehensive literature review of approved ICIs and clinical trials in CRC.
- Analysis of immune checkpoint pathways and tumor microenvironment interactions.
- Evaluation of emerging targets and small-molecule inhibitor strategies.
Main Results:
- Significant advances in ICI therapy over the past decade.
- Limited overall therapeutic efficacy of current ICIs in CRC patients.
- Identification of novel targets and small-molecule inhibitors as promising alternatives.
Conclusions:
- Immune checkpoint-based therapies are crucial but require optimization for CRC.
- Small-molecule inhibitors represent a potential advancement over monoclonal antibodies.
- Future research should focus on innovative strategies to enhance CRC immunotherapy effectiveness.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...